, has been with the team since October 2019. Follow him on Twitter 

Articles

In total, 100% and 93% of those in the SMN two- and three-copy cohorts achieved the primary end point of sitting independently for at least 30 seconds after 18 months of treatment. 

Zolgensma Further Demonstrates Impact in Treating Presymptomatic SMA, Regardless of 2 or 3 SMN2 Copies

Videos

As the individualized needs of patients are further prioritized in Parkinson disease care, the director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute shared her perspective on shared decision-making. [WATCH TIME: 4 minutes]

Involving Patients in the Conversation About Parkinson Disease Treatment Approaches: Jill Farmer, DO, MPH

Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.

Decompressive Craniectomy Shows Greater Improvements in Traumatic Intracranial Hypertension Than Standard Treatment

Head, MS Center, and Senior Physician, University Hospital Basel

The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]

Evobrutinib, BTK Inhibitors, and the Associations With Neurofilament Light: Jens Kuhle, MD, PhD

Here's what is coming soon to NeurologyLive®.

This Week on NeurologyLive® — June 27, 2022

The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed the current methods of prescribing rehabilitation and why a new digital tool can improve them going forward. [WATCH TIME: 3 minutes]

Using Primseq to Simplify the Complexities of Rehabilitation Intervention Dosing: Heidi Schambra, MD

Matt Hoffman, Managing Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive 

 show, Second Opinion. Follow him on Twitter 

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

NeurologyLive® Brain Games: June 26, 2022

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]

Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH

BIIB122, a selective central nervous system-penetrant small molecule inhibitor of LRRK2 is expected to be evaluated in a cohort of 640 patients with early-stage Parkinson disease. 

Phase 2b Study of Parkinson Disease LRRK Inhibitor BIIB122 Initiated

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

All News

Latest News